JP5790965B2 - カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 - Google Patents

カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 Download PDF

Info

Publication number
JP5790965B2
JP5790965B2 JP2014540903A JP2014540903A JP5790965B2 JP 5790965 B2 JP5790965 B2 JP 5790965B2 JP 2014540903 A JP2014540903 A JP 2014540903A JP 2014540903 A JP2014540903 A JP 2014540903A JP 5790965 B2 JP5790965 B2 JP 5790965B2
Authority
JP
Japan
Prior art keywords
angiotensin
antagonist
receptor antagonist
calcium
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014540903A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2014058047A1 (ja
Inventor
一郎 原
一郎 原
友紀子 田中
友紀子 田中
祐幸 樋口
祐幸 樋口
晶子 寺本
晶子 寺本
智也 小野下
智也 小野下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP2014540903A priority Critical patent/JP5790965B2/ja
Application granted granted Critical
Publication of JP5790965B2 publication Critical patent/JP5790965B2/ja
Publication of JPWO2014058047A1 publication Critical patent/JPWO2014058047A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014540903A 2012-10-12 2013-10-11 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 Active JP5790965B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014540903A JP5790965B2 (ja) 2012-10-12 2013-10-11 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012226984 2012-10-12
JP2012226984 2012-10-12
PCT/JP2013/077730 WO2014058047A1 (ja) 2012-10-12 2013-10-11 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
JP2014540903A JP5790965B2 (ja) 2012-10-12 2013-10-11 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014182381A Division JP6302802B2 (ja) 2012-10-12 2014-09-08 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法

Publications (2)

Publication Number Publication Date
JP5790965B2 true JP5790965B2 (ja) 2015-10-07
JPWO2014058047A1 JPWO2014058047A1 (ja) 2016-09-05

Family

ID=50477509

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014540903A Active JP5790965B2 (ja) 2012-10-12 2013-10-11 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
JP2014182381A Active JP6302802B2 (ja) 2012-10-12 2014-09-08 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014182381A Active JP6302802B2 (ja) 2012-10-12 2014-09-08 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法

Country Status (4)

Country Link
JP (2) JP5790965B2 (ko)
KR (2) KR101931489B1 (ko)
TW (1) TW201427720A (ko)
WO (1) WO2014058047A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017210435A (ja) * 2016-05-25 2017-11-30 ダイト株式会社 イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5854371B2 (ja) * 2012-10-12 2016-02-09 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
JP6843498B2 (ja) * 2015-10-14 2021-03-17 Ｅａファーマ株式会社 錠剤、固体分散体顆粒及びその製造方法
JP6967833B2 (ja) * 2015-11-30 2021-11-17 大原薬品工業株式会社 医薬品包装箱を利用した、配合錠の両面印字情報の提供方法
KR101769293B1 (ko) * 2016-09-30 2017-08-30 주식회사 종근당 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504295A (ja) * 1994-08-17 1998-04-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 医薬処方
JP2004002348A (ja) * 2002-03-27 2004-01-08 Bayer Yakuhin Ltd 小型化されたニフェジピン有核錠剤
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
WO2007022113A2 (en) * 2005-08-17 2007-02-22 Novartis Ag Solid dosage forms of valsartan and amlodipine and method of making the same
WO2008002905A2 (en) * 2006-06-27 2008-01-03 Novartis Ag Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
WO2008016171A1 (fr) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Agent prophylactique/thérapeutique destiné à un dysfonctionnement rénal
JP2008044871A (ja) * 2006-08-11 2008-02-28 Ajinomoto Co Inc 心血管疾患予防・治療剤
WO2008032107A1 (en) * 2006-09-15 2008-03-20 Daiichi Sankyo Company Limited Solid dosage form of olmesartan medoxomil and amlodipine
WO2008120724A1 (ja) * 2007-03-30 2008-10-09 Ajinomoto Co., Inc. 固体分散体製剤
WO2010060564A1 (de) * 2008-11-27 2010-06-03 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische darreichungsform enthaltend nifedipin oder nisoldipin und einen angiotensin-ii antagonisten und/oder ein diuretikum
WO2010137855A2 (en) * 2009-05-27 2010-12-02 Dasan Medichem Co., Ltd. Multi-layer tablet comprising effervescent layer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3415291B2 (ja) * 1994-09-27 2003-06-09 味の素ファルマ株式会社 重炭酸透析用剤
RU2245136C2 (ru) * 2001-07-27 2005-01-27 Яманоути Фармасьютикал Ко., ЛТД Композиция, включающая тонкодисперсные частицы с замедленным высвобождением для быстроразлагающихся в щечной полости таблеток, и способ ее получения
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504295A (ja) * 1994-08-17 1998-04-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 医薬処方
JP2004002348A (ja) * 2002-03-27 2004-01-08 Bayer Yakuhin Ltd 小型化されたニフェジピン有核錠剤
WO2007001066A1 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
WO2007022113A2 (en) * 2005-08-17 2007-02-22 Novartis Ag Solid dosage forms of valsartan and amlodipine and method of making the same
WO2008002905A2 (en) * 2006-06-27 2008-01-03 Novartis Ag Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
WO2008016171A1 (fr) * 2006-08-04 2008-02-07 Ajinomoto Co., Inc. Agent prophylactique/thérapeutique destiné à un dysfonctionnement rénal
JP2008044871A (ja) * 2006-08-11 2008-02-28 Ajinomoto Co Inc 心血管疾患予防・治療剤
WO2008032107A1 (en) * 2006-09-15 2008-03-20 Daiichi Sankyo Company Limited Solid dosage form of olmesartan medoxomil and amlodipine
WO2008120724A1 (ja) * 2007-03-30 2008-10-09 Ajinomoto Co., Inc. 固体分散体製剤
WO2010060564A1 (de) * 2008-11-27 2010-06-03 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische darreichungsform enthaltend nifedipin oder nisoldipin und einen angiotensin-ii antagonisten und/oder ein diuretikum
WO2010137855A2 (en) * 2009-05-27 2010-12-02 Dasan Medichem Co., Ltd. Multi-layer tablet comprising effervescent layer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017210435A (ja) * 2016-05-25 2017-11-30 ダイト株式会社 イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法

Also Published As

Publication number Publication date
JP2015003915A (ja) 2015-01-08
KR20160105543A (ko) 2016-09-06
KR101931489B1 (ko) 2018-12-24
TW201427720A (zh) 2014-07-16
WO2014058047A1 (ja) 2014-04-17
KR20150065887A (ko) 2015-06-15
KR101778050B1 (ko) 2017-09-13
JP6302802B2 (ja) 2018-03-28
JPWO2014058047A1 (ja) 2016-09-05

Similar Documents

Publication Publication Date Title
TWI407978B (zh) 濕粒狀藥物之製備方法
CA2338256C (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
JP5898770B2 (ja) 心血管疾患の治療方法
US20020098241A1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
JP2010505943A (ja) 時間治療理論に基づく循環器疾患の治療用組合せ製剤
JP6302802B2 (ja) カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
JP6231959B2 (ja) カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
WO2009113420A1 (ja) オルメサルタンメドキソミルを含む製剤の溶出性の改善
JP2010519200A (ja) シロスタゾールを含む制御放出製剤及びその製造方法
AU750611B2 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
JP5241511B2 (ja) 溶出性の改善された医薬組成物
WO2013098578A1 (en) Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
WO2010026470A1 (en) Stable dosage forms of antihypertensive agents
WO2023247435A1 (en) Bilayer tablets of valsartan and indapamide
EP2521540A2 (en) Solid oral dosage form containing olmesartan medoxomil
MXPA00004791A (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150721

R150 Certificate of patent or registration of utility model

Ref document number: 5790965

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250